Acute arthritis and arthralgia as an adverse drug reaction to dupilumab

Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry

“…One patient switched to a weekly interval before discontinuation. One patient discontinued as a result of nonadherence, and 3 patients discontinued due to severe AEs: monoarthritis of the ankle days after the first dupilumab injection, 14 paradoxical facial erythema, 15 and panniculitis. These complaints resolved after discontinuation.…”

Arthritis and enthesitis during dupilumab therapy completely remitted by celecoxib

“…There have been six reported cases with arthritis or enthesitis whose onset was within 16 weeks after initiation of dupilumab therapy for AD (Table S1). [1][2][3][4] Bridegwood et al 4 found that IL-4/IL-13 suppressed IL-23 expression from digested enthesis tissue treated with lipopolysaccharide. This result indicates that dupilumab can impair the protective role for IL-4/IL-13 in Th17-associated enthesitis.…”

Development of arthralgia during treatment with dupilumab in a patient with atopic dermatitis

“…Dupilumab is a human anti-human interleukin (IL)-4/13 receptor biologic agent that suppresses T-helper (Th)2-type inflammatory responses. 1 Major adverse events include injection site reactions and conjunctivitis.…”

“…At present, only six reports, including the present one, have noted joint symptoms (Figure 1e). [1][2][3] The average patient age was 50.5 years and male : female ratio was 2:1. Only our case resumed F I G U R E 1 Clinical features at the first examination.…”